Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02058160 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
A Phase 3 study of Type 2 Diabetes, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 736
- Enrollment target
- 20
- Study locations
NCT02058160 is a Phase 3 study of Type 2 Diabetes that has completed, run by Sanofi. The registered enrollment target is 736 participants, below the 1,100-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT02058160, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 736 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30. Secondary Objective: To compare the overall efficacy and safety of insulin glargine/lixisenatide FRC to insulin glargine (with or without metformin) over a 30 week treatment period in participants with type 2 diabetes.
Conditions Studied
Interventions
- DRUG Insulin glargine/lixisenatide (HOE901/AVE0010)
- DRUG Insulin glargine (HOE901)
- DRUG Metformin (Background Drug)
Study Locations (20)
California
- Investigational Site Number 840568 - Bell Gardens
- Investigational Site Number 840550 - Chino
- Investigational Site Number 840529 - Chula Vista
- Investigational Site Number 840623 - Corona
- Investigational Site Number 840566 - Fresno
- Investigational Site Number 840552 - Greenbrae
- Investigational Site Number 840578 - Lancaster
- Investigational Site Number 840626 - Los Angeles
- Investigational Site Number 840581 - Los Angeles
- Investigational Site Number 840621 - Mission Viejo
- Investigational Site Number 840511 - Northridge
- Investigational Site Number 840573 - Palm Springs
- Investigational Site Number 840559 - Port Hueneme
- Investigational Site Number 840536 - San Ramon
Arizona
- Investigational Site Number 840570 - Sun City
- Investigational Site Number 840562 - Tempe
- Investigational Site Number 840577 - Tucson
Arkansas
- Investigational Site Number 840517 - Little Rock
- Investigational Site Number 840537 - Little Rock
Alabama
- Investigational Site Number 840607 - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 736 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02058160
The ClinicalTrials.gov registry entry for NCT02058160 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 736 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,100-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (33% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Insulin glargine/lixisenatide (HOE901/AVE0010) is the first listed.
NCT02058160 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02058160 about?
NCT02058160 is a clinical study titled "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes". Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30. Secondary Objective: To compare the overall efficacy and safety of insulin glargine/lixisenatide...
What is the current status of trial NCT02058160?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 736 participants. The study started on 2014-01. Estimated completion is 2015-07.
What conditions does trial NCT02058160 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT02058160?
The interventions under investigation include: Insulin glargine/lixisenatide (HOE901/AVE0010) (DRUG), Insulin glargine (HOE901) (DRUG), Metformin (Background Drug) (DRUG).
Who is sponsoring clinical trial NCT02058160?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02058160 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.